Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - RiceBran Technologiesex31_2.htm
EX-32.1 - EXHIBIT 32.1 - RiceBran Technologiesex32_1.htm
EX-31.1 - EXHIBIT 31.1 - RiceBran Technologiesex31_1.htm


  SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 10-Q/A
 
(Mark one)
x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the quarterly period ended June 30, 2010
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to __________
 
Commission File Number 0-32565
 
 

 
NutraCea
(Exact Name of Registrant as Specified in its Charter)
 
California
(State or other jurisdiction of
incorporation or organization)
 
87-0673375
(I.R.S. Employer Identification No.)
6720 North Scottsdale Road., Suite 390
Scottsdale, AZ
(Address of Principal Executive Offices)
 
 
85253
(Zip Code)
Issuer’s telephone number, including area code:  (602) 522-3000
 
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes o No x
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes o No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer:, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange.
 
Large accelerated filer o    Accelerated filer o
   
Non-accelerated filer o (do not check if a smaller reporting company)  Smaller reporting company x
  
Indicate by check mark whether the registrant is a shell company (as defined in Rule l2b-2 of the Exchange Act).  Yes o No x
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
As of March 15, 2011, 195,509,109 shares of the registrant’s common stock were outstanding.
 


 
1

 
 
Explanatory Note
 
NutraCea is filing this Amendment No. 1 (Amendment) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, filed with the Securities and Exchange Commission on March 31, 2011, (Initial Form 10-Q) to (i) correct the inadvertent omission of the signature page containing the signatures of the chief executive officer and principal financial officer of NutraCea in the Initial Form 10-Q and to include such page in this Amendment and (ii) revise the exhibit list in Item 6.
 
Except for the signature page and exhibit list to the Initial Form 10-Q, no other changes have been made to the Initial Form 10-Q in this Amendment.  This Amendment contains the entirety of the Initial Form 10-Q and Exhibits 31.1, 31.2 and 32.1, which have been updated to today’s date.  This Amendment speaks as of the original filing date of the Initial Form 10-Q, does not reflect events that may have occurred after the original filing date and does not modify or update in any way disclosures made in the Initial Form 10-Q.
 
 
 
 

 
 
 
 
Index
         
PART I.
FINANCIAL INFORMATION
   
         
Item 1.
Unaudited Financial Statements
   
         
 
  3  
           
 
  4  
           
 
  5  
           
 
  6  
           
Item 2.
  23  
           
Item 3.
  31  
           
Item 4.
  31  
       
PART II.
OTHER INFORMATION
  31  
           
Item 1.
  31  
           
Item 1A.
  34  
           
Item 2.
  34  
           
Item 3.
  34  
         
Item 4.
  34  
         
Item 5.
  34  
           
Item 6.
  34  
           
      35  
           
Certifications
         
 
 
2


NutraCea (Debtor in Possession)
 (Unaudited; in thousands, except per share amounts)
 
   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
                         
Revenues
  $ 7,501     $ 9,582     $ 14,723     $ 16,794  
Cost of goods sold
    6,029       7,605       11,519       13,861  
Gross profit
    1,472       1,977       3,204       2,933  
                                 
Operating expenses:
                               
Selling, general and administrative
    3,610       5,409       7,626       11,092  
Professional fees
    507       819       964       1,951  
Impairment of property, plant and equipment
    1,000       -       1,000       -  
Loss on disposal of trademarks, property, plant and equipment
    27       354       403       354  
Provision (recovery) for doubtful accounts receivable and notes receivable
    50       -       123       (64 )
Research and development
    -       155       122       674  
     Total operating expenses     5,194       6,737       10,238       14,007  
                                 
Loss from operations
    (3,722 )     (4,760 )     (7,034 )     (11,074 )
                                 
Other income (expense):
                               
Interest income
    (1 )     158       17       257  
Interest expense
    (300 )     (862 )     (581 )     (1,408 )
Loss on equity method investments
    (10 )     (48 )     (21 )     (52 )
Foreign exchange income (loss)
    -       167       -       (153 )
Warrant liability (expense) income
    (508 )     (123 )     (187 )     1,571  
Other income
    112       -       200       -  
Other expense
    -       (142 )     -       (6 )
     Total other (expense) income     (707 )     (850 )     (572 )     209  
                                 
Reorganization expenses:
                               
Professional fees
    399       -       736       -  
         Total reorganization expenses
    399       -       736       -  
Loss before income taxes
    (4,828 )     (5,610 )     (8,342 )     (10,865 )
Income tax benefit
    300       14       544       200  
Net loss
    (4,528 )     (5,596 )     (7,798 )     (10,665 )
Net loss attributable to noncontrolling interest
    -       5       -       81  
Net loss attributable to NutraCea shareholders
  $ (4,528 )   $ (5,591 )   $ (7,798 )   $ (10,584 )
                                 
Loss per share attributable to NutraCea shareholders
                               
Basic
  $ (0.02 )   $ (0.03 )   $ (0.04 )   $ (0.06 )
Diluted
  $ (0.02 )   $ (0.03 )   $ (0.04 )   $ (0.06 )
                                 
Weighted average number of shares outstanding
                               
Basic
    193,028       180,407       193,010       174,917  
Diluted
    193,028       180,407       193,010       174,917  

 
 
 
3

 

NutraCea (Debtor in Possession)
 (Unaudited; in thousands, except share amounts)
 
   
June 30, 2010
   
December 31, 2009
 
ASSETS
           
Current assets:
           
Cash and cash equivalents   $ 879     $ 952  
Restricted cash     1,916       1,915  
Accounts receivable, net of allowance for doubtful accounts of $277 and $153     3,031       3,506  
Inventories     3,049       3,238  
Notes receivable, current portion, net of allowance for doubtful notes receivable of $636 and $636     1,200       1,200  
Deposits and other current assets     2,300       2,637  
Assets held for sale - property, plant and equipment     9,498       14,551  
Assets held for sale - trademarks     -       650  
Total current assets     21,873       28,649  
                 
Notes receivable, net of current portion
    1,200       1,800  
Property, plant and equipment, net
    24,231       26,243  
Intangible assets, net
    6,801       7,679  
Goodwill
    5,413       5,626  
Equity method investment
    70       91  
Other long-term assets
    91       80  
Total assets   $ 59,679     $ 70,168  
                 
LIABILITIES AND EQUITY
               
Current liabilities:
               
Accounts payable   $ 2,482     $ 2,588  
Accrued expenses     5,389       5,080  
Long-term debt, current portion     5,176       6,642  
Warrant liability, current portion     5       34  
Total current liabilities     13,052       14,344  
                 
Liabilities subject to compromise
    6,953       6,988  
                 
Long-term liabilities:
               
Long-term debt, net of current portion     5,297       5,957  
Deferred tax liability     4,361       5,110  
Warrant liability, net of current portion     1,461       1,245  
Other long-term liabilities     1,000       1,000  
Total liabilities     32,124       34,644  
                 
Commitments and contingencies
               
                 
Equity:
               
Equity attributable to NutraCea shareholders:                
Convertible, series E preferred stock, no par value, $1,000 stated value, 2,743 shares authorized, no shares outstanding     -       -  
Convertible, series D preferred stock, no par value, $1,000 stated value,10,000 shares authorized, no shares outstanding     -       -  
Common stock, no par value, 350,000,000 shares authorized, 193,027,680 and 192,967,680 shares issued and outstanding     205,667       205,291  
Accumulated deficit     (176,942 )     (169,144 )
Accumulated other comprehensive loss     (1,014 )     (467 )
Total equity attributable to NutraCea shareholders     27,711       35,680  
Noncontrolling interest     (156 )     (156 )
Total equity     27,555       35,524  
Total liabilities and equity   $ 59,679     $ 70,168  
 
 
4

 
 NutraCea (Debtor in Possession)
 (Unaudited; in thousands)
 
   
Six Months Ended June 30,
 
   
2010
   
2009
 
Cash flow from operating activities:
           
Net loss
  $ (7,798 )   $ (10,665 )
Adjustments to reconcile net loss to net cash from operating activities:
               
Depreciation and amortization
    2,240       3,540  
Provision for doubtful accounts receivable and notes receivable
    123       (64 )
Impairment of property, plant and equipment
    1,000       -  
Loss on disposal of trademarks, property, plant and equipment
    403       354  
Share-based employee and director compensation
    370       192  
Share-based consultant compensation
    6       -  
Warrant liability expense (income)
    187       (1,571 )
Deferred tax benefit
    (544 )     (210 )
Reorganization expenses
    736       -  
Foreign exchange loss
    -       153  
Loss on equity method investments
    21       52  
Share-based interest expense
    -       844  
Changes in operating assets and liabilities:
               
Trade accounts receivable
    275       (254 )
Inventories
    114       696  
Other current assets
    218       1,399  
Accounts payable and accrued expenses
    377       2,413  
Net cash used in operating activities before reorganization item
    (2,272 )     (3,121 )
                 
Reorganization item - professional fees
    (749 )     -  
Net cash used for reorganization item
    (749 )     -  
Net cash used in operating activities
    (3,021 )     (3,121 )
                 
Cash flows from investing activities:
               
Proceeds from payments on notes receivable
    600       222  
Purchases of property and equipment
    (144 )     (1,202 )
Proceeds from sale of trademarks, property, plant and equipment
    4,356       -  
Distributions received  from equity method investment
    -       -  
Proceeds from sale of equity method investment
    -       -  
Restricted cash
    -       1,683  
Other
    (17 )     -  
Net cash provided by investing activities
    4,795       703  
                 
Cash flows from financing activities:
               
Payments on redemption of convertible, preferred stock
    -       (556 )
Proceeds from noncontrolling interest
    -       32  
Payments of debt
    (1,854 )     (1,881 )
Net cash used in financing activities
    (1,854 )     (2,405 )
                 
Effect of exchange rate changes on cash and cash equivalents
    7       13  
Net decrease in cash and cash equivalents
    (73 )     (4,810 )
Cash and cash equivalents, beginning of year
    952       4,867  
Cash and cash equivalents, end of year
  $ 879     $ 57  
                 
Supplemental disclosures:
               
Cash paid for interest
  $ 413     $ 453  
Cash paid for income taxes
    -       -  

 
 
5

 
NutraCea (Debtor in Possession)
 
Note 1. Basis of Presentation
 
In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“Interim Financial Statements”) of NutraCea and subsidiaries (“we”, “us”, “our” or the “Company”)  were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The Interim Financial Statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.
 
These Interim Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto in our Annual Report on Form 10-K, for the year ended December 31, 2009.
 
The interim results of operations and interim cash flows for the three months and six months ended June 30, 2010 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business.  We have experienced recurring losses and negative cash flows from operations.  In the past we have turned to the equity markets for additional liquidity.  This was not a source of funds during 2010 and 2009 due to our financial position, the state of the equity markets and the bankruptcy filing discussed below.  However, exiting bankruptcy on November 30, 2010, combined with improving financial performance and equity market conditions, may allow us to raise equity funds.  We intend to provide the necessary cash to continue operations through the monetization of certain assets, growth of sales, and possible equity financing transactions.
 
Certain reclassifications have been made to prior period amounts to conform to classifications adopted in the current year.
 
Note 2. Chapter 11 Reorganization, Liquidity and Management’s Plan
 
Chapter 11 Reorganization

On November 10, 2009, NutraCea (the Parent Company) filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code (Bankruptcy Code) in the United States Bankruptcy Court for the District of Arizona (the Bankruptcy Court), in the proceeding entitled In re:  NutraCea, Case No. 2:09-bk-28817-CGC (the Chapter 11 Reorganization).  None of the Parent Company’s subsidiaries, including its Brazilian rice bran oil operation, were included in the bankruptcy filing.  The Parent Company continued to manage its assets and operate its business as “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code.  Under the Bankruptcy Code, certain claims against the Parent Company in existence prior to the filing of the bankruptcy petition were stayed during the pendency of the Chapter 11 Reorganization.  Additional claims arose subsequent to the filing date from the Parent Company’s business operations, its secured borrowing from Wells Fargo Bank, N.A. (Wells Fargo), its employment of professionals, its disposition of certain non-core assets (as described below) and its treatment of certain executory contracts.  The claim of Wells Fargo, the primary secured creditor of the Parent Company, was secured by perfected liens against the Parent Company’s real and personal property, including, without limitation, its plant and equipment, trade receivables and inventory.
 
 
6


On August 10, 2010, the Parent Company and the Official Unsecured Creditors Committee filed with the Bankruptcy Court an amended plan of reorganization (Amended Plan) in accordance with the Bankruptcy Code.  The Amended Plan called for the payment in full of all allowed claims.  Creditors voted overwhelmingly in favor of the Amended Plan and, on October 27, 2010, the Bankruptcy Court entered its order confirming the Amended Plan.  The confirmation order became final on November 10, 2010, and the Amended Plan became effective on November 30, 2010.

In connection with the Chapter 11 Reorganization, we entered into a Senior Secured Super-Priority Debtor-In-Possession Credit and Security Agreement (DIP Credit Agreement), successor loan to the Wells Fargo secured borrowing, which was paid in full as of December 31, 2010.

The liabilities subject to compromise existing at December 31, 2009 became the Parent Company’s payment obligations under the Amended Plan of approximately $7.0 million when the Amended Plan became effective.  As of December 2010, the portion of these obligations remaining unpaid is reflected as pre-petition liabilities.  During 2010, $0.6 million of these obligations were paid with proceeds from the sale of the Phoenix, Arizona building.  Interest accrued on the allowed liabilities subject to compromise from November 2009 through November 2010, at an annual rate of 0.38%.  Interest accrues on the unpaid prepetition liabilities at an annual rate of 8.25% beginning in December 2010.

The Parent Company intends to discharge the obligation to pay these pre-petition liabilities by selling non-core assets, possible equity financing transactions, collecting outstanding receivables, and borrowing on a secured basis.  To secure a portion of these payment obligations, unsecured creditors were granted a lien in all of the Parent Company’s assets.  The lien is administered and may be enforced by a plan agent, who was jointly selected by the Parent Company and the Official Unsecured Creditors Committee.  The plan agent may, among other things, sell specified assets if the payment benchmarks set forth in the Amended Plan are not met.

Under the Amended Plan, if we fail to meet certain benchmarks for payment to our general unsecured creditors as described in the Amended Plan, the plan agent may direct and control the sale of pledged assets as follows:

Benchmark Date
 
Required Cumulative Payment
 
Pledged Assets Subject to Sale by Plan Agent, if Benchmark Not Met 
 
Net Proceeds Plan Agent Retains for the General Unsecured Creditors
July 15, 2011
  50 %  
Dillon, Montana facility and all loose equipment,
 
75% of proceeds from the sale of the facility and up to 100% of the proceeds from the sale of loose equipment
             
October 15, 2011
  75 %  
Dillon, Montana facility and all loose equipment
 
75% of proceeds from the sale of the facility and up to 100% of the proceeds from the sale of loose equipment
             
January 15, 2012
  100 %  
Lake Charles, Louisiana facility and any remaining pledged assets
 
Up to 100% of net proceeds from the sale

Since we will not be able to control the sale of the above assets if we do not meet the payment benchmarks, we cannot guarantee that the assets will be sold at a value satisfactory to us.  As of March 31, 2011, we have made distributions to the general unsecured creditors totaling $3.1 million, or approximately 44% of the amount owed, plus accrued interest.
 
 
7


Under the Amended Plan, the following must be paid to the general unsecured creditors, if and when received:
 
·
75% of the net proceeds from the sale of the Dillon, Montana facility;
 
·
the greater of (i) $2.2 million or (ii) 40% of the first $5.0 million in net proceeds we receive from the monetization of our interest in Nutra SA, LLC (Nutra SA) plus 50% of any net proceeds over $5.0 million;
 
·
50% of the net proceeds from the sale of our interest in Rice Science, LLC or Rice Rx LLC;
 
·
100% of the net proceeds from the sale of any loose (uninstalled) equipment;
 
·
75% of any prepayments received on the note receivable from Ceautamed Worldwide, LLC (Ceautamed), if any, and all receipts on the note beginning April 1, 2011;
 
·
75% of the net proceeds from the sale or monetization of the Lake Charles, Louisiana improvements or Mermentau, Louisiana facility, after payment of professional fees;
 
·
75% of the net proceeds from the sale or monetization of any other pledged assets;
 
·
100% of any recoveries from avoidance actions or actions against former officers and directors.
 
Liquidity and Management’s Plans

The Parent Company and it’s wholly and majority owned subsidiaries have experienced recurring losses and negative cash flows from operations.  Due to defaults under our credit agreement with Wells Fargo our credit lines were reduced to approximately $3.5 million as of July 2009, which was the level of the current outstanding loans and obligations at that time.  We also entered into a forbearance agreement with Wells Fargo pursuant to which Wells Fargo agreed to forebear from exercising its rights and remedies with respect to the existing defaults.  We were behind on our payments to vendors and had defaulted on several agreements due to non-payment resulting in declaring bankruptcy as described above.  Although we emerged from bankruptcy in November 2010, we have not yet demonstrated the ability to generate sufficient cash flows from operations to meet our working capital needs.  These factors raise substantial doubt about our ability to continue as a going concern.

We have taken steps to improve profitability and liquidity by reducing our U.S. based employee headcount at both the corporate and plant operations level.  The reductions in force that occurred at various times throughout 2009 resulted in annualized savings of approximately $2.4 million (unaudited).  In January 2010, an additional corporate reduction in force was enacted resulting in annualized savings of $0.8 million (unaudited).  Effective January 1, 2010, we moved our corporate headquarters to less expensive office space resulting in yearly rent savings of approximately $1.2 million (unaudited).  The combined effect of the cost cutting efforts total $4.4 million (unaudited).

In the ongoing effort to improve profitability, significant emphasis will be placed on growing sales. The growth of revenues is expected to include the following:

·
growing sales in existing markets, including bulk Stabilized Rice Bran (SRB) and rice bran oil;
·
aligning with strategic partners who can provide channels for additional sales of our products including rice-bran oil extraction;
·
price increases; and
·
growing consumer retail product sales.

In the past we have turned to the equity markets for additional liquidity.  This was not a source of funds during 2010 and 2009 due to our financial position, the state of the equity markets and the bankruptcy filing.  However, exiting bankruptcy on November 30, 2010, combined with improving financial performance and equity market conditions, may allow us to raise equity funds.  We intend to provide the necessary cash to continue operations through the monetization of certain assets, growth of sales, and possible equity financing transactions.  Asset monetization may include some or all of the following:
 
 
8


·
sale or a sale-lease back of certain facilities;
·
sale of a noncontrolling interest in one or more subsidiaries; or
·
sale of surplus equipment.
 
Some of these sales could result in additional non-cash write downs of asset values.  Although management believes that they will be able to obtain the funds necessary to continue as a going concern there can be no assurances that our efforts will prove successful.  The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Note 3. General Business

We are a food ingredient and health company focused on the procurement, processing and refinement of rice bran and derivative products.  We have proprietary intellectual property that allows us to process and convert rice bran, one of the world’s most underutilized food resources, into a highly nutritious ingredient, stabilized rice bran (SRB) that has applications in various food products.  Our target markets are food manufacturers, nutraceuticals and animal nutrition.  It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both domestically and internationally.  These products include food supplements and nutraceuticals which provide health benefits for humans and animals based on SRB and SRB derivatives.  We believe that SRB products can deliver beneficial physiological effects.  We are continuing to pursue ongoing clinical trials and third party analyses in order to further support the uses for and effectiveness of our products.  In addition, NutraCea has developed a bio-refining approach to processing stabilized rice bran into various value added constituents such as rice bran oil (RBO), defatted rice bran (DRB) and a variety of other valuable derivatives of rice bran.

We have three reportable business segments: (1) Corporate; (2) SRB, which manufactures and distributes SRB in various granulations along with products derived from bran via patented enzyme treatment processes including a fat and protein rich water soluble fraction and a fiber rich insoluble fraction; and (3) Bio-Refining, which separates rice bran into crude rice bran oil and defatted rice bran which are then further processed into a number of valuable food and feed products.  Bio-Refining operations consisted of our operations in Brazil in 2010 and 2009.  The Corporate segment includes selling, general and administrative expenses, litigation settlements, and other expenses not directly attributable to other segments.  No corporate allocations are made to the other segments.  Interest is not allocated.
 
Note 4.  Loss Per Share (EPS)
 
Basic EPS is computed by dividing net loss attributable to NutraCea shareholders by the weighted average number of common shares outstanding during all periods presented.  Options, warrants and shares available upon conversion of preferred stock are excluded from the basic EPS calculation and are considered in calculating the diluted EPS.

Diluted EPS is computed by dividing net loss attributable to NutraCea shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises or conversions is dilutive.  The dilutive effect of outstanding options and warrants is calculated using the treasury stock method.  The dilutive effect of outstanding convertible preferred stock is calculated using the “if converted” method.  
 
 
9


Reconciliations of the numerators and denominators in the EPS computations follow:
 
   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2010
   
2009
   
2010
   
2009
 
NUMERATOR (in thousands):
                       
Basic and diluted - net loss attributable to NutraCea shareholders
  $ (4,528 )   $ (5,591 )   $ (7,798 )   $ (10,584 )
                                 
DENOMINATOR:
                               
Basic EPS - weighted average number of shares outstanding
    193,027,680       180,406,806       193,009,779       174,916,509  
Effect of dilutive securities outstanding
    -       -       -       -  
Diluted EPS - weighted average number of shares outstanding
    193,027,680       180,406,806       193,009,779       174,916,509  
                                 
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive-
                               
Stock options (average exercise price of $0.43 and $0.79)
    26,594,147       22,734,388       26,612,186       23,179,397  
Warrants (average exercise price of $1.27 and $1.39)
    39,578,506       35,800,701       39,711,103       35,309,955  
 

The impact of certain options and warrants outstanding at June 30, 2010 and 2009, were not included in the calculation of diluted EPS in 2010 and 2009, because to do so would be antidilutive.  Those securities which were antidilutive in 2010 and 2009 could potentially dilute EPS in the future.

Note 5. Comprehensive Loss
 
Comprehensive loss consists of the following:
 
   
Three Months Ended
June 30,
   
Six Months Ended
June 30,
 
   
2010
   
2009
   
2010
   
2009
 
                         
Net loss
  $ (4,528 )   $ (5,596 )   $ (7,798 )   $ (10,665 )
                                 
Other comprehnsive income (loss) - foreign currency translation, net of tax
    (140 )     2,001       (547 )     (3,806 )
                                 
Comprehensive loss, net of tax
    (4,668 )     (3,595 )     (8,345 )     (14,471 )
                                 
Comprehensive loss attributable to the noncontrolling interest
    -       5       -       81  
                                 
Total comprehensive loss attribibutable to NutraCea shareholders
  $ (4,668 )   $ (3,590 )   $ (8,345 )   $ (14,390 )
 
10


Accumulated other comprehensive loss, as reflected on the Condensed Consolidated Balance Sheets, is comprised of the following:
 
   
June 30, 
2010
   
December 31,
2009
 
Foreign currency translation adjustment
  $ (1,014 )   $ (467 )
Accumulated other comprehensive loss
  $ (1,014 )   $ (467 )

Note 6. Irgovel and Nutra SA Membership Interest Purchase Agreement

In December 2010, we entered into a membership interest purchase agreement with AF Bran Holdings-NL LLC and AF Bran Holdings LLC (the Investors).  The transaction closed in January 2011.  The Investors agreed to purchase units in Nutra SA for an aggregate purchase price of $7.7 million.  Prior to the transaction, Nutra SA was our wholly owned subsidiary.  Nutra SA owns 100% of Irgovel.  Initially after the close, effective in January 2011, we own a 64.4% interest in Nutra SA, and the Investors own a 35.6% interest in Nutra SA.  The Parent Company received $4.0 million of the proceeds.  The remaining amount of $3.7 million, less $0.5 million retained by Nutra SA for administrative expenses, was invested in Irgovel for capital improvements and working capital needs.

The Parent Company agreed to use $2.2 million of the funds received from the January 2011 transaction closing to repay amounts owed to the general unsecured creditors in accordance with the Amended Plan.  The remaining $1.8 million was used for general corporate purposes, unsecured creditor claims and administrative expenses associated with the Chapter 11 Reorganization.

We are restricted from competing with Nutra SA and Irgovel in Brazil as further described in the purchase agreement.  In addition, upon the occurrence of certain events and conditions as described in the purchase agreement, the Investors may be required to purchase a number of units of Nutra SA from the Parent Company, at $2.00 per unit, resulting in the Investors holding up to a 49.0% interest in Nutra SA.  The Parent Company anticipates receiving on or about March 31, 2011, an additional $1.0 million from the Investors for the purchase of additional units in Nutra SA.  The purchase will increase the Investors’ interest in Nutra SA by 4.6%, to a 40.2% interest.

In 2011, we will consolidate the results of the operations of Nutra SA.  The Investors’ interest in Nutra SA will be reflected as a noncontrolling interest.  The amount of gain or loss, if any, resulting from the Investors’ purchases of interests in Nutra SA has yet to be determined.

Note 7. Settlement with Herbal Science

In March 2010, Herbal Science Singapore Pte. Ltd. (HS) filed a proof of claim against the Parent Company in the amount of $1.5 million in the Chapter 11 Reorganization.  In November 2010, we entered into a stipulated settlement agreement with HS and certain affiliates, which was subsequently approved by the Bankruptcy Court.  The stipulation provides that, by no later than January 2011, we will pay HS $0.9 million.  Upon HS’s receipt of the payment:

 
a.
We will assume the Rice Rx LLC (RRX) and Rice Science, LLC (RS) limited liability company agreements, together with a related supply agreement and license agreements, and the proof of claim will be deemed satisfied;
 
b.
HS will assign to us all of its interests in the RRX and RS limited liability companies;
 
c.
HS and the affiliates will assign to us any interest they have in the patentable pharmaceuticals, SRB isolates and related intellectual property;
 
d.
HS will assign to us the supply agreement, the license agreement and certain related research and development agreements;
 
 
11

 
 
e.
HS and the affiliates will agree not to engage in any research, development, sale, distribution, commercialization, and/or manufacturing activities concerning the patentable pharmaceuticals, SRB isolates and related intellectual property;
 
f.
HS and the affiliates will agree to cooperate with us in specified ways to protect, preserve and perfect the patentable pharmaceuticals, SRB isolates and related intellectual property; and
 
g.
The parties will waive and release all claims against each other in regard to the limited liability companies, the supply agreement, the license agreement and the research and development agreements.
 
In January 2011, we renegotiated the stipulated settlement agreement with HS and the affiliates to provide that the payment of $0.9 million would be deferred until we receive the balance of the purchase price for the sale of up to a 49% interest in Nutra SA or until funds otherwise become available earlier.  Until we satisfy our payment obligation to HS, HS has an allowed claim for $0.9 million and will receive distributions as a general unsecured creditor without priority.  We expect to pay our obligation in full no later than April 2011.

Note 8. Assets Held for Sale – Property, Plant and Equipment
 
The following is a summary of property, plant and equipment held for sale (in thousands):
 
   
June 30,
2010
   
December 31,
2009
 
Land
  $ 2,928     $ 2,928  
Plant
    4,569       5,569  
Machinery and equipment
    2,001       4,813  
Construction in progress
    -       1,241  
Assets held for sale - property, plant and equipment
  $ 9,498     $ 14,551  

   
June 30,
2010
   
December 31,
2009
 
Dillon facility
  $ 4,498     $ 4,492  
Phoenix building
    5,000       6,000  
Phoenix equipment
    -       4,059  
Assets held for sale - property, plant and equipment
  $ 9,498     $ 14,551  
 
Dillon facility

Our Dillon, Montana facility produces certain retail products - RiSolubles, RiFiber and RiBalance.  In addition, Dillon produces infant cereal products under a tolling agreement.  In October 2009, as part of evaluating non-core assets and businesses, management determined that the Dillon facility (which included land, building and equipment) would be offered for sale.  We began to aggressively market the Dillon facility in January 2010 once an agreement to sell the infant cereal business was entered into in December 2009.  A written offer to purchase the facility was received in January 2010 for $5.3 million.  Subsequently, the offer was withdrawn by the prospective buyer.  The net book value of the land, building and equipment as of March 31, 2010, was $4.5 million and no impairment was noted at that time, as we believed we could sell all the assets of Dillon at or above net book value. It is a fully functional facility.

Throughout 2010, we aggressively marketed the facility.  The facility is classified as held for sale as of June 30, 2010 and December 31, 2009.

Based on an evaluation of market conditions and a discounted cash flow analyses we recognized an impairment loss of $0.9 million in the fourth quarter of 2010.
 
 
12


In February 2011, we ceased actively marketing the facility.  We continue to operate the facility for toll processing and are evaluating ways to utilize excess capacity.  As a result, in the first quarter of 2011, we reclassified the Dillon facility to property, plant and equipment in use and restarted depreciation.

Phoenix Building and Equipment
 
Our Phoenix, Arizona building was constructed to produce infant and adult cereal for worldwide sale.  When additional sales did not materialize, we determined that the cereal production could be adequately handled at the Dillon, Montana facility.  In July 2009, we decided to sell our infant cereal manufacturing building located in Phoenix, Arizona as well as the equipment housed in the building.  The building was listed for sale in September 2009, and based on our best judgment and prevailing market conditions; we recorded a noncash impairment charge of $6.5 million in September 2009 associated with the building.  In December 2009, an offer was received to purchase the cereal equipment.  As a result, we decided to sell the equipment and building separately.  Based on offers received from potential buyers, we recognized an additional impairment of $1.0 million on the building in the second quarter of 2010.  The building was sold in September 2010 for a gross price of $4.5 million.  We recorded a loss on disposal in 2010 of $0.5 million plus closing costs.
 
The cereal equipment was sold in March 2010 for $3.7 million pursuant to the December 2009 offer, upon Bankruptcy Court approval.  We recorded a loss on disposal of $0.3 million during the first quarter of 2010.
 
We determined that the cereal product line did not constitute a component of the overall business entity and thus it has not been reported as a discontinued operation.
 
We used the proceeds from the sale of the building to (i) pay the remaining $1.8 million owed under the DIP Credit Agreement, (ii) pay the $1.4 million owed for all mechanic’s liens secured by the property, closing costs and property taxes, (iii) pay $1.0 million of unsecured creditor obligations and (iv) provide $0.3 million of funding for our exit from bankruptcy.

Lake Charles

Our Lake Charles, Louisiana facility was built at a cost of $3.8 million to process rice bran from a rice milling company adjacent to the facility.  The facility was idled in May 2009 due to lack of orders.  The facility is built on leased land which is owned by the rice milling company.  Due to non-payment of the lease rent, the rice milling company served us with a foreclosure notice in July 2009.  Upon receipt, management initiated discussions with the rice milling company to possibly sell them the building.  In September 2009, management made a written offer to sell the building for $1.3 million which was not accepted.  As a result of the written offer, we recorded an impairment of $2.3 million in 2009.  The facility is not classified as held for sale due to potential alternative uses and because we are not aggressively marketing the property.  We evaluated, and continue to evaluate, alternate uses of the facility which could include serving as an oil pressing operation or serving as a warehouse to store and distribute DRB produced in Brazil.

Corporate Office

In November 2009, the Bankruptcy Court approved our motion to reject our old corporate office lease and to enter into a new, less expensive, corporate office lease.  We relocated our headquarters in December 2009.  As a result in December 2009, we recorded a $4.0 million loss on disposal of the leasehold improvements and furniture and fixtures associated with the old corporate office.  The loss on disposal was partially off-set by (i) a $1.1 million tenant improvement and moving allowance deferred credit related to the prior lease and (ii) $0.2 million of net proceeds from an auction of the furniture and fixtures.  Since the old corporate lease was rejected under the bankruptcy procedures, the resulting charge has been included within reorganization expenses in the consolidated statements of operations.  In addition, approximately $0.2 million of non-cash charge was recorded related to furniture and fixtures relocated to the new corporate office. 
 
 
13

 
Note 9. Asset Held  for Sale - Intangible
 
In July 2009, we decided to sell our animal nutrition product related equine trademarks in order to stop competing with major customers.  We initiated discussions with several potential buyers to sell a supply agreement and the trademarks for $0.8 million.  An offer of $0.7 million was received from an existing customer of equine products in December 2009.  The $2.2 million net book value of the trademarks was reduced to $0.7 million, with impairment charges totaling $1.5 million in 2009.  The equine trademarks representing a value of $0.7 million were classified as assets held for sale – trademarks as of December 31, 2009.  
 
In March 2010, Manna Pro Products, LLC (Manna Pro) agreed to purchase from us (i) the Natural Glo, Satin Finish and Max-E-Glow trademarks and intellectual property for $0.7 million and (ii) certain supplies and inventory.  In April 2010, the asset sale closed and total consideration was $0.8 million.  As a condition to the sale, we agreed to supply Manna Pro with the stabilized rice bran they require to utilize the purchased assets.  All products sold by Manna Pro under the trademarks being purchased will be co-branded with a NutraCea SRB logo.  In the second and third quarter of 2009, a $1.6 million non-cash charge related to the assets sold is reflected as loss on impairment of trademarks in our consolidated statements of operations.
 
Note 10.  Equity and Share-Based Compensation
 
The following is a summary of stock option activity:
 
   
Number of
Options
   
Weighted
Average
Exercise
Price
Outstanding at December 31, 2009
    24,588,951     $ 0.49
Granted
    3,488,889       0.20
Exercised
    -        
Forfeited/expired
    (1,487,992 )     1.24
Outstanding at June 30, 2010
    26,589,848       0.41
Exercisable at June 30, 2010
    20,225,514     $ 0.47
 
 
 
   
Number of
Options
   
Weighted
Average
Exercise
Price
Outstanding at December 31, 2008
    25,193,477     $ 0.80
Granted
    400,000       0.30
Forfeited/expired
    (2,868,544 )     1.01
Outstanding at June 30, 2009
    22,724,933       0.77
Exercisable at June 30, 2009
    21,633,104     $ 0.75
 
 
14

 
In July 2010, we modified 3,045,347 outstanding options, which had been awarded to employees.  The exercise price of the options was lowered to $0.20 per share from a weighted average $0.40 per share.  The stock price on the date of the re-pricing was $0.12 per share.  No other terms of the options were modified.  We recorded expense of less than $0.1 million in the third quarter 2010, representing the difference between the fair value of the options before and after the modification.

In the period from July 2010 to March 2011, approximately 22.1 million options were issued at an average price of $0.20 per share.  In the same period, approximately 9.1 million options at an average exercise price of $0.34 per share were forfeited, expired or cancelled.

In December 2010, we reached an agreement to settle all potential claims associated with the employment of Brad Edson, our former chief executive officer.  The agreement was subject to the approval of the Bankruptcy Court which was granted in January 2011.  As part of the settlement, he was required to forfeit 6,000,000 options granted in 2004 along with any stock holdings.  The options had an exercise price of $0.30 per share and were outstanding and exercisable as of June 30, 2010 and 2009.

In March 2011, we reached an agreement to settle all potential claims associated with the employment of Todd Crow, our former chief financial officer.  As part of the settlement, he was required to forfeit 1,662,942 options.  The agreement is subject to the approval of the Bankruptcy Court which is currently pending.  The options had an average exercise price of $0.37 per share and were outstanding and exercisable as of June 30, 2010 and 2009.

Note 11. Commitments and Contingencies

Purchase and Supply Commitments

In January 2011, Irgovel entered into a commitment to supply $0.4 million of crude rice bran oil each month from April 2011 to December 2011.  The commitment represents approximately 50% of Irgovel’s crude oil production capacity.

In January 2011, Irgovel entered into equipment purchase commitments totaling approximately $5.6 million.  The equipment is part of a capital project to expand production capacity and improve operational efficiency. We expect to pay for this equipment during the first nine months of 2011.

Litigation

In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business.  When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations.

Defense costs are expensed as incurred and are included in professional fees.
 
 
15


Irgovel Stockholders Lawsuit

On August 28, 2008, former Irgovel stockholder David Resyng filed an indemnification suit against Irgovel, Osmar Brito and the remaining Irgovel stockholders (Sellers), requesting: (i) the freezing of the escrow account maintained in connection with the transfer of Irgovel’s corporate control to us and the presentation of all documentation related to the transaction, and (ii) damages in the amount of the difference between (a) the sum received by David Resyng in connection with the judicial settlement agreement executed in the action for the partial dissolution of the limited liability company filed by David Resyng against Irgovel and the Sellers and (b) the amount received by the Sellers in connection with the sale of Irgovel’s corporate control to us, in addition to moral damages as determined in the court’s discretion.  The amount of damage claimed by Mr. Resyng is approximately $3 million.

We believe that the filing of the above lawsuit is a fundamental default of the obligations undertaken by the Sellers under the Quotas Purchase Agreement for the transfer of Irgovel’s corporate control, executed by and among the Sellers and us on January 31, 2008 (Purchase Agreement).  Consequently, we believe that the responsibility for any indemnity, costs and expenses incurred or that may come to be incurred by Irgovel and/or us in connection with the above lawsuit is the sole responsibility of the Sellers.

On February 6, 2009, the Sellers filed a collection lawsuit against us seeking payment of the second installment of the purchase price under the Purchase Agreement, which the Sellers allege is approximately $1.0 million.  We have withheld payment of the second installment pending resolution of the Resyng lawsuit noted above.  The Parent Company has not been served with any formal notices in regard to this matter so far.  To date, only Irgovel has received formal legal notice. In addition, the Purchase Agreement requires that all disputes between us and the Sellers be adjudicated through arbitration. As part of the Purchase Agreement $2.0 million was deposited into an escrow account to cover contingencies with the net remaining funds payable to the Sellers upon resolution of all contingencies.  We believe any payout due to the lawsuit will be made out of the escrow account.  As of June 30, 2010 and December 31, 2009, the balance in the escrow account was $1.9 million and is included in restricted cash in the consolidated balance sheets.  There is an offsetting liability in accrued expenses in our condensed consolidated balance sheets as of June 30, 2010 and December 31, 2009.  We believe that there is no additional material exposure as any amounts determined to be owed as a result of the above noted litigation and contingencies will be covered by the escrow account.

Shareholder Class Action

On February 27, 2009 and on April 27, 2009, securities class action lawsuits were filed in the District Court for the District of Arizona against us and certain of our current and former officers and directors.  On May 29, 2009, the cases were consolidated into a single action (the Federal Action) and lead plaintiff was appointed.  On July 1, 2009, lead plaintiff filed a consolidated class action complaint on behalf of all persons who purchased our common stock between April 2, 2007 and February 23, 2009.  The complaint alleged that we filed material misstatements in publically disseminated press releases and SEC filings misstating our financial condition and certain transactions during the period in question.  An amended consolidated complaint was filed on September 25, 2009.

The case has been settled in its entirety with the settlement to be funded by our directors and officers insurance carrier.  On October 1, 2010, the District Court of Arizona issued an order approving the settlement, certifying the class and entering judgment dismissing the matter.  On October 27, 2010, the Bankruptcy Court also entered an order approving the settlement.

Shareholder Derivative Action

In addition to the shareholder class actions, on March 30, 2009 and May 8, 2009, two shareholder derivative lawsuits were filed in Maricopa County Superior Court by persons identifying themselves as our shareholders and purporting to act on our behalf, naming us as a nominal defendant and naming our former chief executive officer and our then board of directors as defendants.
 
 
16


In these actions, the plaintiffs asserted claims against the individual defendants for breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets, and unjust enrichment based on the alleged wrongful conduct complained of in the federal action described above.  All of these claims were purportedly asserted derivatively on our behalf and the plaintiffs sought no monetary recovery against us.  Instead they sought, among other relief, disgorgement of all profits, benefits, and compensation received by the individual defendants together with their attorneys’ fees and costs.
 
By an order entered on June 3, 2009, the superior court consolidated these two cases into one action captioned In re:  NutraCea Derivative Litigation, Case No. CV2009-051495.  Following the filing of the Chapter 11 Reorganization, the defendants filed a motion to dismiss the action for lack of standing.  On February 10, 2010, in response to that motion, plaintiffs filed a voluntary dismissal without prejudice of both actions and the court entered the dismissals.

SEC Enforcement Investigation

We received a letter from the SEC in January 2009 indicating that it had opened an informal inquiry, and we subsequently received an informal request for the production of documents in February 2009 relating to a number of 2007 transactions.  In March 2009, we received a formal order of private investigation from the SEC.  In June 2009, we received a subpoena for the production of documents that largely tracked the SEC’s earlier requests.  We responded to these requests for documents and based on findings related to the internal review and the SEC’s requests, we restated our financial statements for 2006, 2007 and the first three quarters of 2008.

On January 13, 2011, the SEC filed a complaint in the United States District Court for the District of Arizona alleging that we violated Section 17(a) of the Securities Act of 1933 (Securities Act), 15 U.S.C. § 77q(a), Sections 10(b), 13(a), 13(b)(2)(A), and 13(b)(2)(B) of the Exchange Act of 1934 (the Exchange Act), 15 U.S.C. §§ 78j(b), 78m(a), 78m(b)(2)(A), and 78m(b)(2)(B), and Rules 10b-5, 12b-20, 13a-1, and 13a-13 thereunder, 17 C.F.R. §§ 240.10b-5, 240.12b-20, 240.13a-1, and 240.13a-13 (the SEC Action).  We have settled these allegations with the SEC, without admitting or denying them, and have consented to the entry of a final judgment of permanent injunction (the Consent Judgment), which, among other things, permanently restrains and enjoins us from violations of Section 17(a) of the Securities Act, 15 U.S.C. § 77q(a), Sections 10(b), 13(a), 13(b)(2)(A), and 13(b)(2)(B) of the Exchange Act, 15 U.S.C. §§ 78j(b), 78m(a), 78m(b)(2)(A), and 78m(b)(2)(B), and Rules 10b-5, 12b-20, 13a-1, and 13a-13 thereunder, 17 C.F.R. §§ 240.10b-5, 240.12b-20, 240.13a-1, and 240.13a-13.  The final Consent Judgment was entered in the SEC action on February 14, 2011.  No financial penalty was assessed by the SEC against us.

W.D. Manor Mechanical Contractors, Inc. and Related Matters

On April 30, 2009, W.D. Manor Mechanical Contractors, Inc. (W.D. Manor) filed a complaint against us and other unrelated defendants in Superior Court of Arizona, Maricopa County (CV2009-013957) arising out of the construction of a facility in Phoenix, Arizona.  Various other sub-contractors joined in the lawsuit and asserted lien claims.  These claims have been accrued and expensed in our consolidated financial statements.  With the sale of the Phoenix facility in September 2010, all claims held by W.D. Manor and the other subcontractors who joined in the lawsuit, totaling $0.7 million, were paid in full from the proceeds of the sale and the lawsuit was dismissed. 

Farmers’ Rice Milling

Farmers’ Rice Milling (FRM) contended that we defaulted by failing to pay rentals due under two leases between the parties: (i) the March 15, 2007, ground lease, as amended on November 1, 2008, and (ii) the April 15, 2007, warehouse lease.  FRM filed suit against us to terminate the leases and recover damages thereunder.  This suit was filed in the 14th Judicial District Court on June 24, 2009, and was timely removed to the United States District Court, Western District of Louisiana, Lake Charles division.  We filed an answer and counterclaim and deposited into the registry of the court $0.1 million constituting the rentals due under the leases, a late fee due under the warehouse lease plus accrued interest.  As part of the Chapter 11 Reorganization, the leases were assumed under Section 365 of the Bankruptcy Code.  Arrearages due under the leases were paid in January 2011 and the lawsuit was dismissed.  FRM also asserted a claim for monetary damages for breach of a supply agreement, but that claim was dismissed from the lawsuit and allowed as a general unsecured claim in the Chapter 11 Reorganization.
 
 
17

 
Note 12. Segment Information

We have three reportable segments: Corporate; Stabilized Rice Bran (SRB), which manufactures and distributes SRB in various granulations along with products derived from bran via patented enzyme treatment processes including a fat and protein rich water soluble fraction and a fiber rich insoluble fraction; and Bio-Refining, which separates rice bran into crude rice bran oil and defatted rice bran which are then further processed into a number of valuable food and feed products.  The Bio-Refining segment consisted of our Irgovel operations in Brazil in 2010 and 2009.  The Corporate segment includes corporate general and administrative expenses, litigation settlements, and other expenses not directly attributable to segments.  No corporate allocations are made to the other segments.  Interest is not allocated.

The table below presents segment information for the years identified and provides a reconciliation of segment information to total consolidated information.
 
   
Three Months Ended June 30, 2010
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
            (1)     (2)      
Revenues
  $ -     $ 3,303     $ 4,198     $ 7,501  
Cost of goods sold
    -       2,058       3,971       6,029  
Gross profit
    -       1,245       227       1,472  
Depreciation and amortization (in selling, general and administrative)
    (56 )     (352 )     (269 )     (677 )
Impairment of property, plant and equipment
    -       (1,000 )     -       (1,000 )
Loss on disposal of trademarks, property, plant and equipment
    -       (27 )     -       (27 )
Other operating expenses
    (2,004 )     (733 )     (753 )     (3,490 )
Loss from operations
  $ (2,060 )   $ (867 )   $ (795 )   $ (3,722 )
                                 
Net loss attributable to NutraCea shareholders
  $ (3,076 )   $ (867 )   $ (585 )   $ (4,528 )
Interest expense
    (102 )     -       (198 )   $ (300 )
Depreciation (in cost of goods sold)
    -       (105 )     (319 )   $ (424 )
Purchases of property and equipment
    -       2       82       84  
Property, plant and equipment, end of period
    1,978       9,922       12,331       24,231  
Assets held for sale, end of period
    -       9,498       -       9,498  
Goodwill, end of period
(3)
  -       -       5,413       5,413  
Intangible assets, net, end of period
    -       3,273       3,528       6,801  
 
 
18

 
   
Three Months Ended June 30, 2009
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
            (1)     (2)      
Revenues
  $ -     $ 4,182     $ 5,400     $ 9,582  
Cost of goods sold
    -       3,210       4,395       7,605  
Gross profit
    -       972       1,005       1,977  
Depreciation and amortization (in selling, general and administrative)
    (251 )     (747 )     (235 )     (1,233  )
Loss on disposal of trademarks, property, plant and equipment
    -       (354 )     -       (354 )
Other operating expenses
    (2,405 )     (1,897 )     (848 )     (5,150 )
Loss from operations
  $ (2,656 )   $ (2,026 )   $ (78 )   $ (4,760 )
                                 
Net loss attributable to NutraCea shareholders
  $ (4,008 )   $ (1,676 )   $ 93     $ (5,591 )
Interest expense
    (639 )     -       (223 )     (862 )
Depreciation (in cost of goods sold)
    -       (293 )     (268 )     (561 )
Purchases of property and equipment
    159       -       71       230  
Property, plant and equipment, end of period
    7,126       34,075       12,710       53,911  
Assets held for sale, end of period
    -       639       -       639  
Goodwill, end of period
(3)
  -       -       5,067       5,067  
Intangible assets, net, end of period
    -       6,428       3,991       10,419  
 
 
   
Six Months Ended June 30, 2010
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
            (1)     (2)      
Revenues
  $ -     $ 6,537     $ 8,186     $ 14,723  
Cost of goods sold
    -       4,081       7,438       11,519  
Gross profit
    -       2,456       748       3,204  
Depreciation and amortization (in selling, general and administrative)
    (114 )     (686 )     (550 )     (1,350  )
Impairment of property, plant and equipment
    -       (1,000 )     -       (1,000 )
Loss on disposal of trademarks, property, plant and equipment
    -       (403 )     -       (403 )
Other operating expenses
    (4,166 )     (1,727 )     (1,592 )     (7,485 )
Loss from operations
  $ (4,280 )   $ (1,360 )   $ (1,394 )   $ (7,034 )
                                 
Net loss attributable to NutraCea shareholders
  $ (5,377 )   $ (1,360 )   $ (1,061 )   $ (7,798 )
Interest expense
    (253 )     -       (328 )     (581 )
Depreciation (in cost of goods sold)
    -       (251 )     (639 )     (890 )
Purchases of property and equipment
    15       8       121       144  
Property, plant and equipment, end of period
    1,978       9,922       12,331       24,231  
Assets held for sale, end of period
    -       9,498       -       9,498  
Goodwill, end of period
(3)
  -       -       5,413       5,413  
Intangible assets, net, end of period
    -       3,273       3,528       6,801  
 
 
19

 
   
Six Months Ended June 30, 2009
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
            (1)     (2)      
Revenues
  $ -     $ 7,978     $ 8,816     $ 16,794  
Cost of goods sold
    -       6,134       7,727       13,861  
Gross profit
    -       1,844       1,089       2,933  
Depreciation and amortization (in selling, general and administrative)
    (497 )     (1,412 )     (450 )     (2,359  )
Loss on disposal of trademarks, property, plant and equipment
    -       (354 )     -       (354 )
Other operating expenses
    (5,998 )     (3,888 )     (1,408 )     (11,294 )
Loss from operations
  $ (6,495 )   $ (3,810 )   $ (769 )   $ (11,074 )
                                 
Net loss attributable to NutraCea shareholders
  $ (6,134 )   $ (3,729 )   $ (721 )   $ (10,584 )
Interest expense
    (1,082 )     -       (326 )     (1,408 )
Depreciation (in cost of goods sold)
    -       (668 )     (513 )     (1,181 )
Purchases of property and equipment
    524       495       183       1,202  
Property, plant and equipment, end of period
    7,126       34,075       12,710       53,911  
Assets held for sale, end of period
    -       639       -       639  
Goodwill, end of period
(3)
  -       -       5,067       5,067  
Intangible assets, net, end of period
    -       6,428       3,991       10,419  
 
(1)  The SRB segment was formerly referred to as “NutraCea”.
(2)  The Bio-Refining segment was formerly referred to as “Irgovel”.
(3)  All changes in goodwill between December 31, 2009 and June 30, 2010, relate to foreign currency translation.
 
The following tables present data by geographic area:
 
   
Three Months Ended
June 30,
   
Six Months Ended
June 30,
   
2010
   
2009
   
2010
   
2009
                       
United States
  $ 2,343     $ 3,222     $ 4,794     $ 6,494
Brazil
    4,191       5,280       8,178       8,500
Other international
    967       1,080       1,751       1,800
Total revenues
  $ 7,501     $ 9,582     $ 14,723     $ 16,794
 
   
June 30,
2010
   
December 31,
2009
           
United States
  $ 11,900     $ 12,678
Brazil
    12,331       13,565
Total property, plant and equipment, net
  $ 24,231     $ 26,243
 
Note 13. Fair Value Measurement
 
As defined in ASC No. 820, Fair Value Measurements (“ASC 820”), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value.  Assets and liabilities measured at fair value on a recurring basis include warrant liabilities.   Assets and liabilities measured at fair value on a non-recurring basis include held-for-sale property, plant and equipment and held-for-sale trademarks.
 
 
20

 
We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market:
 
 
Level 1 – inputs include quoted prices for identical instruments and are the most observable.
 
 
Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves.
 
 
Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability.
 
For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed.
 
The following table summarizes the fair values by input hierarchy of items measured at fair value on a recurring basis on our condensed consolidated balance sheets (in thousands):
 
         
As of June 30, 2010
         
Level 1
   
Level 2
   
Level 3
   
Total
                             
Warrant liability
    (1 )   $ -     $ -     $ 1,466     $ 1,466
Total liabilities at fair value
          $ -     $ -     $ 1,466     $ 1,466
           
 
As of December 31, 2009
           
Level 1
   
Level 2
   
Level 3
   
Total
                                       
Warrant liability
    (1 )   $ -     $ -     $ 1,279     $ 1,279
Total liabilities at fair value
          $ -     $ -     $ 1,279     $ 1,279
 
(1)  
Represents fair value of warrant liability established as a result of adoption of FASB ASC 815, “Derivatives and Hedging” (FASB ASC 815) (previously EITF 07-5, “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity’s Own Stock).  Fair value of the warrant liabilities was determined using the Lattice Model.
 
The following tables summarize the changes in level 3 items measured at fair value on a recurring basis (in thousands):
 
    June 30, 2010        
   
Fair Value as of Beginning of Year
   
Total
Realized/ Unrealized
Gains (Losses)
   
Issuance of
New Warrants
   
Net
Transfers
Into (Out of)
 Level 3
   
Fair Value, at
June 30, 2010
   
Change in Unrealized Gains (Losses) on Instruments Still Held
 
            (1 )                        
Warrant liability
  $ 1,279     $ (187 )   $ -     $ -     $ 1,466     $ (187 )
Total Level 3 fair value
  $ 1,279     $ (187 )   $ -     $ -     $ 1,466     $ (187 )
 
 
21

 
   
June 30, 2009
       
   
Adoption of ASC 815-40-15 as of Beginning of Year
   
Total
Realized/ Unrealized
Gains (Losses)
   
Record Series D Warrants at Fair Value as of Beginning of Year
   
Issuance of
New Warrants
   
Net
Transfers
Into (Out of)
 Level 3
   
Fair Value, at
March 31, 2009
   
Change in Unrealized Gains (Losses) on Instruments Still Held
 
          (1)        (1)        (1)                      
Warrant liability
  $ 3,913     $ (3,503 )   $ 1,156     $ 776     $ -     $ 2,342     $ (3,503 )
Total Level 3 fair value
  $ 3,913     $ (3,503 )   $ 1,156     $ 776     $ -     $ 2,342     $ (3,503 )
 
(1)  
Included in warrant liability income (expense) in the condensed consolidated statements of operations.

The following tables summarize the fair values by input hierarchy of items measured at fair value on our condensed consolidated balance sheets on a non-recurring basis (in thousands):
 
         
As of June 30, 2010
 
         
Level 1
   
Level 2
   
Level 3
   
Total
 
                               
Assets held for sale - property, plant and equipment
    (1 )   $ -     $ -     $ 9,498     $ 9,498  
Total assets at fair value
          $ -     $ -     $ 9,498     $ 9,498  
 
         
As of December 31, 2009
 
         
Level 1
   
Level 2
   
Level 3
   
Total
 
                               
Assets held for sale - property, plant and equipment
    (1 )   $ -     $ -     $ 14,551     $ 14,551  
Assets held for sale - trademarks
    (2 )     -       -       650       650  
Lake Charles building
    (3 )     -       -       1,251       1,251  
Total assets at fair value
          $ -     $ -     $ 16,452     $ 16,452  

(1)
Represents land, building and equipment at our Dillon, Montana and Phoenix, Arizona facilities.  The fair value was measured based on third party appraisals, offers from potential buyers, management’s judgment and subsequent sale of the assets, less costs to sell.

(2)
Represents equine trademarks held for sale as of December 31, 2009.  We determined the fair value based on the offers received from potential buyers.  The equine trademarks were sold to an existing customer of our equine products in April 2010.

(3)
We recorded an impairment of $2.3 million in 2009.  The fair value of the building was based on a written offer made to FRM and a third party appraisal.
 
Note 14. Events in Japan

As of March 31, 2011, we have not experienced any unfavorable impact on revenues from the March 2011 earthquake and tsunami which devastated Japan, or its aftermath.  Shipments of our rice bran oil product to a southern port in Japan have been unaffected.  Although not foreseen at this time, we may experience unfavorable impacts on our operating results in the future should the situation change.
 
 
22

 
 
The following discussion and analysis addresses material changes in the results of operations and financial condition of NutraCea and subsidiaries (“we”, “us”, “our” or the “Company,”) for the periods presented. This discussion and analysis should be read in conjunction with the Condensed Consolidated Financial Statements, the related Notes to Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Results of Operations and Financial Condition included in the Company’s Annual Report on Form 10-K, for the year ended December 31, 2009, the unaudited interim Condensed Consolidated Financial Statements and related Notes included in Part I — Item 1 of this Quarterly Report on Form 10-Q (“Form 10-Q”) and the Company’s other Securities and Exchange Commission (“SEC”) filings and public disclosures.
 
This Form 10-Q may contain “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the Company’s market opportunities, strategies, competition and expected activities and expenditures, and at times may be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “intend”, “continue” and variations of these words or comparable words. Forward-looking statements inherently involve risks and uncertainties. Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Current Report on Form 10-Q and in our annual Report on Form 10-K for the year ended December 31, 2009. The Company undertakes no obligation to update any forward-looking statements for revisions or changes after the filing date of this Form 10-Q.
 
We are a food ingredient and health company focused on the procurement, processing and refinement of rice bran and derivative products.  We have proprietary intellectual property that allows us to process and convert rice bran, one of the world’s most underutilized food resources, into a highly nutritious ingredient, stabilized rice bran (SRB) that has applications in various food products.  Our target markets are food manufacturers, nutraceuticals and animal nutrition.  It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both domestically and internationally.  These products include food supplements and nutraceuticals which provide health benefits for humans and animals based on SRB and SRB derivatives.  We believe that SRB products can deliver beneficial physiological effects.  We are continuing to pursue ongoing clinical trials and third party analyses in order to further support the uses for and effectiveness of our products.  In addition, NutraCea has developed a bio-refining approach to processing stabilized rice bran into various value added constituents such as rice bran oil (RBO), defatted rice bran (DRB) and a variety of other valuable derivatives of rice bran.

We have three reportable business segments: (1) Corporate; (2) Stabilized Rice Bran (SRB), which manufactures and distributes SRB in various granulations along with products derived from bran via patented enzyme treatment processes including a fat and protein rich water soluble fraction and a fiber rich insoluble fraction; and (3) Bio-Refining, which separates rice bran into crude rice bran oil and defatted rice bran which are then further processed into a number of valuable food and feed products.  The Corporate segment includes selling, general and administrative expenses, litigation settlements, amortization of intangible assets, and other expenses not directly attributable to other segments.  No corporate allocations are made to the other segments.  Interest is not allocated.

The SRB segment consists of four locations in California and Louisiana that produce SRB. Not included in these four locations is our Phoenix, Arizona facility, which became operational in February 2009 but was never brought into full production. The Phoenix facility was sold in September 2010. Our Lake Charles, Louisiana facility has been idle since May 2009. The SRB segment also includes our Dillon, Montana facility which produces RiSolubles (a highly nutritious, carbohydrate and lipid rich fraction), RiFiber (a fiber rich derivative) and RiBalance (a complete rice bran nutritional package). The Dillon facility, which consists of land, building and equipment, has been carried as an asset held for sale as of December 31, 2009.
 
 
23

 
The manufacturing facilities included in our SRB segment have specialized processing equipment and techniques for the treatment of rice grain products to cook, convert, isolate, dry and package finished food ingredients used in the formulation of health food and consumer food finished products. In addition, we have the capability to custom manufacture various grain based products for human food ingredient companies at our Dillon facility.
 
The Bio-Refining segment consists of our Irgovel operations in Brazil.  Irgovel manufactures RBO and DRB products for both the human and animal food markets in Brazil and internationally.  Irgovel owns the largest rice bran processing facility in South America and is the only Brazilian company to produce edible RBO for human consumption.  In refining RBO to an edible grade several co-products are obtained, including distilled fatty acids, a valuable raw material for the detergent industry.  DRB is compounded with a number of other ingredients to produce complex animal feeds which are packaged and sold under Irgovel brands in the Brazilian market.    
  
RESULTS OF OPERATIONS
 
THREE MONTHS ENDED JUNE 30, 2010 AND 2009
 
For the three months ended June 30, 2010, the Company’s net loss was $4.5 million, or ($.02) per share, compared to $5.6 million or ($.03) per share for the same period of 2009, an improvement of $1.1 million. The decrease in net loss was primarily due to a combination of significantly reduced selling, general and administrative expenses for the Corporate and SRB segments partially offset by: (i) reduced gross profit, (ii) impairment of the Phoenix facility, and (iii) reorganization expenses associated with the bankruptcy filing.
 
Revenue and Gross profit

The following table illustrates the gross profit contribution by each of our segments:
 
   
Three Months Ended June 30, 2010
       
   
Consolidated
   
%
   
SRB
   
%
   
Bio-Refining
   
%
   
Increase/ (Decrease)
 
Revenues
  $ 7,501       100     $ 3,303       100     $ 4,198       100       (2,081 )
Cost of good sold
    6,029       80       2,058       62       3,971       95       (1,576 )
Gross profit
  $ 1,472       20     $ 1,245       38     $ 227       5     $ (505 )
 
   
Three Months Ended June 30, 2009
 
   
Consolidated
   
%
   
SRB
   
%
   
Bio-Refining
   
%
 
Revenues
  $ 9,582       100     $ 4,182       100     $ 5,400       100  
Cost of good sold
    7,605       79       3,210       77       4,395       81  
Gross profit
  $ 1,977       21     $ 972       23     $ 1,005       19  

Our consolidated revenues for the three months ended June 30, 2010 of $7.5 million decreased by $2.1 million (21.7%) from $9.6 million in the prior year period. Revenues for the SRB segment decreased $0.9 million (21%) and the Bio-Refining segment decreased by $1.2 million (22.2%). SRB segment revenues were negatively impacted by three factors in 2010. Revenues declined by $0.6 million due to the sale of the equine product related assets (primarily trademarks, packaging materials and inventory) in April 2010. As a result of the transaction, we no longer sell higher priced branded equine products and instead supply bulk SRB to the buyer (Manna Pro). Because Manna Pro purchased existing inventory on hand, they did not begin purchasing SRB until late in the 2010 quarter. In addition, the cereal product related sales declined by a net $24 thousand as a result of the March 2010 sale of the cereal product related assets to Kerry Ingredients (Kerry). The loss of cereal revenues was partially offset by tolling revenues billed to Kerry. Under the tolling arrangement, we continue to produce certain cereal products for Kerry on an order by order basis. And finally, SRB segment revenues were negatively impacted by $0.4 million from the loss of a private label customer related to products we no longer sell. The Bio-Refining segment revenues decreased as a result of lower volumes partially offset by improved pricing in 2010.
 
 
24

 
Gross profit in the three months ended June 30, 2010 was $1.5 million (20%) compared to $2.0 million (21%) in 2009, a decrease of $0.5 million attributable to the decline in revenues. The SRB segment experienced a significant improvement of $0.3 million due to the high cost of goods sold incurred in 2009 attributed to higher raw bran prices and the loss of lower margin product revenues in 2010. The Bio-Refining segment was negatively impacted by higher plant operating costs associated with maintenance and general improvements along with lower plant utilization.  

Operating Expenses

Specific changes in the components of operating expense are detailed in the following schedule:
 
   
Three Months Ended June 30, 2010
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
Selling, general and administrative
  $ 1,723     $ 1,017     $ 870     $ 3,610  
Professional fees
    336       69       102       507  
Impairment of property, plant and equipment
    -       1,000       -       1,000  
Loss on disposal of trademarks, property, plant and equipment
    -       27       -       27  
Provision for doubtful accounts receivable and notes receivable
    -       -       50       50  
Research and development
    -       -       -       -  
Operating expenses
  $ 2,059     $ 2,113     $ 1,022     $ 5,194  
                                 
   
Three Months Ended June 30, 2009
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
Selling, general and administrative
  $ 1,954     $ 2,470     $ 985     $ 5,409  
Professional fees
    702       18       99       819  
Impairment of property, plant and equipment
    -       -       -       -  
Loss on disposal of trademarks, property, plant and equipment
    -       354       -       354  
Provision for doubtful accounts receivable and notes receivable
    -       -       -       -  
Research and development
    -       155       -       155  
Operating expenses
  $ 2,656     $ 2,997     $ 1,084     $ 6,737  
                                 
   
Favorable (Unfavorable) Change
 
   
Corporate
   
SRB
   
Bio-Refining
   
Consolidated
 
Selling, general and administrative
  $ 231     $ 1,453     $ 115     $ 1,799  
Professional fees
    366       (51 )